openPR Logo
Press release

Biosimilars Market : Global Industry Forecast, Market Application Analysis, Market Size and Industry Outlook 2015-2022 |Brisk Insights

04-27-2016 12:50 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Brisk Insights

Biosimilars Market : Global Industry Forecast, Market

According to a recently published report, the Biosimilars Market is expected to grow at the CAGR of 22.6% during 2015-2022. The segmentation of global biosimilars market is based on product type, application, technology, services and geography. The report on Global Biosimilars Market Forecast, 2015-2022 (by product type, application, technology, services and geography) provides detailed overview and predictive analysis of the market.
Increasing number of off patented drugs, rising pressure to decrease healthcare expenditure and cost effectiveness are the various factors that are driving the growth of global biosimilars market.

Detailed study on this Research :http://www.briskinsights.com/report/biosimilars-market

Market players are implementing various growth strategies in the market to gain a competitive edge. New product launch, product pipelines, agreements and collaborations were certain major strategies adopted by players. Some of the challenges faced by biosimilars market are fledgling regulatory framework and various manufacturing related issues.

For Same Category Reports Visit Here: http://www.briskinsights.com/category/pharmaceutical-industry

Scope of the report
1. Global Biosimilar market by product type, 2012 - 2022 ($ billion)
1.1. Recombinant Peptides
1.1.1. Glucagon
1.1.2. Calcitonin
1.2. Recombinant Glycosylated Proteins
1.2.1. Erythropoietin (EPO)
1.2.2. Follitropin
1.2.3. Monoclonal Antibodies (MABS)
1.3. Recombinant Non-Glycosylated Proteins
1.3.1. Interferons
1.3.2. Recombinant Human Growth Hormone (RHGH)
1.3.3. Granulocyte Colony-Stimulating Factor (Filgrastim)
1.3.4. Insulin

2. Global Biosimilar market by application type, 2012 - 2022 ($ billion)
2.1. Blood Disorders
2.2. Chronic and Autoimmune Diseases
2.3. Growth Hormone Deficiency
2.4. Infectious Diseases
2.5. Other Applications

3. Global Biosimilar market by technology, 2012 - 2022 ($ billion)
3.1. Nuclear magnetic resonance technology
3.2. Western blotting
3.3. Monoclonal antibodies technology
3.4. Electrophoresis
3.5. Chromatography
3.6. Bioassay
3.7. Recombinant DNA technology
3.8. Mass spectrometry

4. Global Biosimilar market by technology, 2012 - 2022 ($ billion)
4.1. Clinical trials
4.2. Contract research & manufacturing services (CRMS)

5. Global Biosimilar market , regional outlook, 2012-2022(in $billion)
5.1. North America
5.2. Europe
5.3. Asia Pacific
5.4. Middle East & Africa
5.5. Latin America
6. Company profiles
6.1. Amgen
6.2. Biocon Ltd.
6.3. Celltrion, Inc.
6.4. Dr. Reddy's Laboratories
6.5. Hospira,inc
6.6. Merck KGAA
6.7. Mylan, Inc.
6.8. Roche Diagnostics
6.9. Sandoz International GmbH
6.10. Teva Pharmaceutical Industries Ltd.
6.11. Stada Arzneimittel AG
6.12. Ratiopharm GmbH
6.13. Intas Pharmaceuticals Ltd.
6.14. LG Life Sciences
6.15. Synthon Pharmaceuticals, Inc.

Here you can find Free Sample on this Research : http://www.briskinsights.com/sample-request/136

Blog :http://www.pdfdevices.com/global-biosimilars-market-is-expected-to-grow-at-the-cagr-of-22-6-during-2015-2022-brisk-insights/

Contact Us :
Jennifer Smith
Office 1094
109 Vernon House
Friar Lane
nottingham
NG1 6DQ
Phone : +448081890034 (UK)
Email : sales@briskinsights.com
Website : http://www.briskinsights.com/

About Us :

Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities optimize strategies.
Working in a highly dynamic and multi-dimensional business makes decision making complex. Effective business decisions are a result of the synthesis of market information. Our Research and data analysis is an efficient and cost-effective way of providing robust market analysis and can yield highly valuable intelligence relating to consumers, competitors and markets.

Office 1094
109 Vernon House
Friar Lane

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilars Market : Global Industry Forecast, Market Application Analysis, Market Size and Industry Outlook 2015-2022 |Brisk Insights here

News-ID: 336297 • Views:

More Releases from Brisk Insights

Global Refrigerated Display Cases (RDC) Market - Growth, Future Prospects & Comp …
According to a new market research report published by Brisk Insights, "Refrigerated Display Cases (RDC) Market (by Product Type (Plug-in RDCs & Remote RDCs), by Product Design (Vertical - Front Open, Horizontal - Top Open, and Others (Hybrid, etc.)), By End-use (Food Service Establishments & Retail Establishments), by Geography (North America, Europe, Asia Pacific, and Rest of the World)) - Growth, Future Prospects, and Competitive Landscape, 2019 -2027", the global
Increased Adoption Of Cloud-Based Services And Big Data Analytics To Drive Deman …
According to a new market report published by Acute Market Reports, "Global Data Center Cooling Market (By Product (Air conditioners, Chillers, Cooling Towers, Economizers, and Other Equipment), By Cooling Technique (Air-based Cooling, and Liquid-based Cooling), By Cooling Architecture (Room, Rack, and Row)) - Growth, Share, Opportunities, Competitive Analysis, and Forecast 2017 - 2025", the global data center cooling market is expected to witness strong growth during the forecast period 2017
Pharmacy Dispensing Machines Market Is Expected To Reach US$ 6,023.2 Mn By 2026
The latest market report published by Brisk Insights “Global Pharmacy Dispensing Machines Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” the global pharmacy dispensing machines market was valued at US$ 3,222.2 Mn in 2017, and is expected to reach US$ 6,023.2 Mn by 2026, expanding at a CAGR of 7.3% from 2018 to 2026. Market Insights Every year billions of dollars are wasted by the healthcare agencies throughout the globe
Global Ambulatory Care Services Market Is Expected To Reach US$ 106.8 Bn By 2025
The latest market report published by Brisk Insights “Global Ambulatory Care Services Market - Market Growth, Future Prospects, Competitive Analysis and Pipeline Analysis, 2017 - 2025,” the global ambulatory care services market was valued at US$ 72.96 Bn in 2016, and is expected to reach US$ 106.8 Bn by 2025 expanding at a CAGR of 4.22 % from 2017 to 2025. Market Insights According to World Health Organization in 2013 approximately 33%

All 4 Releases


More Releases for Biosimilar

Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.